Eli Lilly and Company $LLY Position Reduced by Premier Path Wealth Partners LLC

Premier Path Wealth Partners LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 1.3% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 6,067 shares of the company’s stock after selling 79 shares during the period. Premier Path Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $4,730,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the 1st quarter worth approximately $27,000. Blume Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the period. IMG Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter valued at $35,000. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the first quarter valued at $40,000. Finally, TD Capital Management LLC raised its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.1%

LLY opened at $810.78 on Thursday. The business has a 50 day moving average price of $775.02 and a 200 day moving average price of $770.34. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $767.37 billion, a P/E ratio of 52.99, a price-to-earnings-growth ratio of 1.22 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Guggenheim restated a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Morgan Stanley cut their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the company an “overweight” rating in a research note on Thursday, October 9th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.